Track ERNA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$27.24M
Enterprise Value$57.61M
Revenue (TTM)-
Net Income (TTM)-$14.08M
Free Cash Flow (TTM)-$7.05M
Financial Health
Cash$1.88M
Net Debt$30.37M
Debt Ratio5.53
Debt to Equity13.43
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-1.93
EV to EBITDA-6.93
Price to Book11.35
Price to Free Cash Flow-3.86
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-309.67%
Return on Assets-202.05%
Return on Equity-971.90%
Return on Total Capital-309.67%
Return on Capital Employed-340.02%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (3Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (1Y)
Revenue-100.00%
Diluted EPS1000.00%
Total Debt2.90%
Capital Expenditures-89.97%
Free Cash Flow1000.00%
$4.48-$0.06|-1.34%
Last updated: Jul 22, 3:44 PM ET
52W High$71.50
52W Low$3.18
50D SMA$7.94
200D SMA$18.25
Volume48.59K
Eterna Therapeutics Inc
1035 Cambridge Street, Cambridge, MA, United States, 02141
IPO
1992
Employees
5
Industry
Biotechnology
Sector
Healthcare
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20220+2
2
Analyst Ratings
No coverage data
No analyst ratings data available